{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:46:04Z","timestamp":1793807164205,"version":"4.6.1"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["222096\/Z\/20\/Z"],"award-info":[{"award-number":["222096\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIHR UCLH Biomedical Research Centre"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41409-026-02906-0","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:57:37Z","timestamp":1779447457000},"page":"791-804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Updated EBMT\/ESID inborn errors working party guidelines for haematopoietic stem cell transplantation for inborn errors of immunity and metabolism"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9143-3263","authenticated-orcid":false,"given":"M. H.","family":"Albert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6703-2993","authenticated-orcid":false,"given":"A. C.","family":"Lankester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6046-8428","authenticated-orcid":false,"given":"R.","family":"Wynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. R.","family":"Gennery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9165-1690","authenticated-orcid":false,"given":"M.","family":"Hoenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kreins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4834-1130","authenticated-orcid":false,"given":"E. C.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Slatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8941-0935","authenticated-orcid":false,"given":"B.","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation and the European Society for Immune Deficiencies, and the European Reference Network on Rare Primary Immunodeficiency Autoinflammatory Autoimmune diseases (RITA)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2906_CR1","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1038\/s41409-021-01378-8","volume":"56","author":"AC Lankester","year":"2021","unstructured":"Lankester AC, Albert MH, Booth C, Gennery AR, G\u00fcng\u00f6r T, H\u00f6nig M, et al. EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity. Bone Marrow Transplant. 2021;56:2052\u201362. https:\/\/doi.org\/10.1038\/s41409-021-01378-8.","journal-title":"Bone Marrow Transplant"},{"key":"2906_CR2","doi-asserted-by":"publisher","unstructured":"Poli MC, Aksentijevich I, Bousfiha AA, Cunningham-Rundles C, Hambleton S, Klein C et al. Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee. J Hum Immun. 2025;1. https:\/\/doi.org\/10.70962\/jhi.20250003.","DOI":"10.70962\/jhi.20250003"},{"key":"2906_CR3","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41586-024-08346-4","volume":"637","author":"O Stewart","year":"2025","unstructured":"Stewart O, Gruber C, Randolph HE, Patel R, Ramba M, Calzoni E, et al. Monoallelic expression can govern the penetrance of inborn errors of immunity. Nature. 2025;637:1186\u201397. https:\/\/doi.org\/10.1038\/s41586-024-08346-4.","journal-title":"Nature"},{"key":"2906_CR4","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood.2022015506","volume":"140","author":"MH Albert","year":"2022","unstructured":"Albert MH, Sirait T, Eikema DJ, Bakunina K, Wehr C, Suarez F, et al. Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study. Blood. 2022;140:1635\u201349. https:\/\/doi.org\/10.1182\/blood.2022015506.","journal-title":"Blood"},{"key":"2906_CR5","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1182\/blood.2021014687","volume":"139","author":"MH Albert","year":"2022","unstructured":"Albert MH, Slatter MA, Gennery AR, G\u00fcng\u00f6r T, Bakunina K, Markovitch B, et al. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis. Blood. 2022;139:2066\u201379. https:\/\/doi.org\/10.1182\/blood.2021014687.","journal-title":"Blood"},{"key":"2906_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jaci.2023.10.018","volume":"153","author":"M Fischer","year":"2024","unstructured":"Fischer M, Olbrich P, Hadjadj J, Aumann V, Bakhtiar S, Barlogis V, et al. JAK inhibitor treatment for inborn errors of JAK\/STAT signaling: an ESID\/EBMT-IEWP retrospective study. J Allergy Clin Immunol. 2024;153:275\u2013286.e218. https:\/\/doi.org\/10.1016\/j.jaci.2023.10.018.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR7","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.jaci.2021.10.017","volume":"149","author":"AC Lankester","year":"2022","unstructured":"Lankester AC, Neven B, Mahlaoui N, von Asmuth EGJ, Courteille V, Alligon M, et al. Hematopoietic cell transplantation in severe combined immunodeficiency: The SCETIDE 2006-2014 European cohort. J Allergy Clin Immunol. 2022;149:1744\u20131754.e1748. https:\/\/doi.org\/10.1016\/j.jaci.2021.10.017.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1182\/blood.2024024038","volume":"144","author":"SH Lum","year":"2024","unstructured":"Lum SH, Albert MH, Gilbert P, Sirait T, Algeri M, Muratori R, et al. Outcomes of HLA-mismatched HSCT with TCR\u03b1\u03b2\/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity. Blood. 2024;144:565\u201380. https:\/\/doi.org\/10.1182\/blood.2024024038.","journal-title":"Blood"},{"key":"2906_CR9","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1182\/blood.2024026915","volume":"145","author":"Q Riller","year":"2025","unstructured":"Riller Q, Hauri M, Lum SH, Knippenberg J, Sirait T, Laberko A, et al. HLA-haploidentical stem cell transplantation for chronic granulomatous disease: an EBMT-IEWP retrospective study. Blood. 2025;145:2518\u201327. https:\/\/doi.org\/10.1182\/blood.2024026915.","journal-title":"Blood"},{"key":"2906_CR10","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2022017667","volume":"141","author":"C Schuetz","year":"2023","unstructured":"Schuetz C, Gerke J, Ege M, Walter J, Kusters M, Worth A, et al. Hypomorphic RAG deficiency: impact of disease burden on survival and thymic recovery argues for early diagnosis and HSCT. Blood. 2023;141:713\u201324. https:\/\/doi.org\/10.1182\/blood.2022017667.","journal-title":"Blood"},{"key":"2906_CR11","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.jaci.2024.08.020","volume":"154","author":"C Tsilifis","year":"2024","unstructured":"Tsilifis C, Speckmann C, Lum SH, Fox TA, Soler AM, Mozo Y, et al. Hematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: a European Society for Blood and Marrow Transplantation Inborn Errors Working Party study. J Allergy Clin Immunol. 2024;154:1534\u201344. https:\/\/doi.org\/10.1016\/j.jaci.2024.08.020.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR12","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1182\/blood.2019002939","volume":"135","author":"LM Burroughs","year":"2020","unstructured":"Burroughs LM, Petrovic A, Brazauskas R, Liu X, Griffith LM, Ochs HD, et al. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood. 2020;135:2094\u2013105. https:\/\/doi.org\/10.1182\/blood.2019002939.","journal-title":"Blood"},{"key":"2906_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1182\/blood.2022016196","volume":"140","author":"GDE Cuvelier","year":"2022","unstructured":"Cuvelier GDE, Logan BR, Prockop SE, Buckley RH, Kuo CY, Griffith LM, et al. Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC. Blood. 2022;140:685\u2013705. https:\/\/doi.org\/10.1182\/blood.2022016196.","journal-title":"Blood"},{"key":"2906_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jaci.2023.09.027","volume":"153","author":"H Eissa","year":"2024","unstructured":"Eissa H, Thakar MS, Shah AJ, Logan BR, Griffith LM, Dong H, et al. Posttransplantation late complications increase over time for patients with SCID: a Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study. J Allergy Clin Immunol. 2024;153:287\u201396. https:\/\/doi.org\/10.1016\/j.jaci.2023.09.027.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/s0140-6736(23)00731-6","volume":"402","author":"MS Thakar","year":"2023","unstructured":"Thakar MS, Logan BR, Puck JM, Dunn EA, Buckley RH, Cowan MJ, et al. Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the primary immune deficiency treatment consortium. Lancet. 2023;402:129\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(23)00731-6.","journal-title":"Lancet"},{"key":"2906_CR16","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.20.25322586","author":"G Kindle","year":"2025","unstructured":"Kindle G, Alligon M, Albert MH, Buckland M, Edgar JD, Gathmann B, et al. Inborn errors of immunity: manifestation, treatment, and outcome - an ESID registry 1994-2024 report on 30,628 patients. Prepr Serv Health Sci. 2025. https:\/\/doi.org\/10.1101\/2025.02.20.25322586.","journal-title":"Prepr Serv Health Sci"},{"key":"2906_CR17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.anai.2025.02.026","volume":"134","author":"S Wijeyesinghe","year":"2025","unstructured":"Wijeyesinghe S, Chinen J. Gene therapy for inborn errors of immunity: Current clinical progress. Ann Allergy, Asthma Immunol. 2025;134:630\u20138. https:\/\/doi.org\/10.1016\/j.anai.2025.02.026.","journal-title":"Ann Allergy, Asthma Immunol"},{"key":"2906_CR18","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2502754","volume":"393","author":"C Booth","year":"2025","unstructured":"Booth C, Masiuk K, Vazouras K, Fernandes A, Xu-Bayford J, Campo Fernandez B, et al. Long-term safety and efficacy of gene therapy for adenosine deaminase deficiency. N Engl J Med. 2025;393:1486\u201397. https:\/\/doi.org\/10.1056\/NEJMoa2502754.","journal-title":"N Engl J Med"},{"key":"2906_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2025.104384","volume":"47","author":"G Consiglieri","year":"2025","unstructured":"Consiglieri G, Tucci F, Bernardo ME. Hematopoietic stem cell gene therapy of neurometabolic lysosomal storage diseases. Brain Dev. 2025;47:104384. https:\/\/doi.org\/10.1016\/j.braindev.2025.104384.","journal-title":"Brain Dev"},{"key":"2906_CR20","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41409-025-02701-3","volume":"60","author":"R Greco","year":"2025","unstructured":"Greco R, Ruggeri A, McLornan DP, Snowden JA, Alexander T, Angelucci E, et al. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations. Bone Marrow Transplant. 2025;60:1499\u2013525. https:\/\/doi.org\/10.1038\/s41409-025-02701-3.","journal-title":"Bone Marrow Transplant"},{"key":"2906_CR21","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1182\/blood.2023021411","volume":"143","author":"TC Vall\u00e9e","year":"2024","unstructured":"Vall\u00e9e TC, Glasmacher JS, Buchner H, Arkwright PD, Behrends U, Bondarenko A, et al. Wiskott-Aldrich syndrome: a study of 577 patients defines the genotype as a biomarker for disease severity and survival. Blood. 2024;143:2504\u201316. https:\/\/doi.org\/10.1182\/blood.2023021411.","journal-title":"Blood"},{"key":"2906_CR22","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1182\/blood.2020005590","volume":"136","author":"R Chiesa","year":"2020","unstructured":"Chiesa R, Wang J, Blok HJ, Hazelaar S, Neven B, Moshous D, et al. Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. Blood. 2020;136:1201\u201311. https:\/\/doi.org\/10.1182\/blood.2020005590.","journal-title":"Blood"},{"key":"2906_CR23","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/cid\/ciw837","volume":"64","author":"B Dunogu\u00e9","year":"2017","unstructured":"Dunogu\u00e9 B, Pilmis B, Mahlaoui N, Elie C, Coignard-Biehler H, Amazzough K, et al. Chronic granulomatous disease in patients reaching adulthood: a nationwide study in France. Clin Infect Dis. 2017;64:767\u201375. https:\/\/doi.org\/10.1093\/cid\/ciw837.","journal-title":"Clin Infect Dis"},{"key":"2906_CR24","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1016\/j.jaci.2018.12.1010","volume":"143","author":"F Ferrua","year":"2019","unstructured":"Ferrua F, Galimberti S, Courteille V, Slatter MA, Booth C, Moshous D, et al. Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT\/ESID-IEWP-SCETIDE-PIDTC study. J Allergy Clin Immunol. 2019;143:2238\u201353. https:\/\/doi.org\/10.1016\/j.jaci.2018.12.1010.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10875-014-0126-0","volume":"35","author":"SE Aydin","year":"2015","unstructured":"Aydin SE, Kilic SS, Aytekin C, Kumar A, Porras O, Kainulainen L, et al. DOCK8 deficiency: clinical and immunological phenotype and treatment options - a review of 136 patients. J Clin Immunol. 2015;35:189\u201398. https:\/\/doi.org\/10.1007\/s10875-014-0126-0.","journal-title":"J Clin Immunol"},{"key":"2906_CR26","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1182\/blood.2020006738","volume":"136","author":"S Ghosh","year":"2020","unstructured":"Ghosh S, K\u00f6stel Bal S, Edwards ESJ, Pillay B, Jim\u00e9nez Heredia R, Erol Cipe F, et al. Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency. Blood. 2020;136:2638\u201355. https:\/\/doi.org\/10.1182\/blood.2020006738.","journal-title":"Blood"},{"key":"2906_CR27","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jaci.2017.10.041","volume":"141","author":"F Barzaghi","year":"2018","unstructured":"Barzaghi F, Amaya Hern\u00e1ndez LC, Neven B, Ricci S, Kucuk ZY, Bleesing JJ, et al. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: an international multicenter retrospective study. J Allergy Clin Immunol. 2018;141:1036\u20131049.e1035. https:\/\/doi.org\/10.1016\/j.jaci.2017.10.041.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR28","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/s41409-020-0800-1","volume":"55","author":"GA Rotulo","year":"2020","unstructured":"Rotulo GA, Beaupain B, Rialland F, Paillard C, Nachit O, Galambrun C, et al. HSCT may lower leukemia risk in ELANE neutropenia: a before-and-after study from the French Severe Congenital Neutropenia Registry. Bone Marrow Transplant. 2020;55:1614\u201322. https:\/\/doi.org\/10.1038\/s41409-020-0800-1.","journal-title":"Bone Marrow Transplant"},{"key":"2906_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.932385","volume":"13","author":"H Hashem","year":"2022","unstructured":"Hashem H, Dimitrova D, Meyts I. Allogeneic hematopoietic cell transplantation for patients with deficiency of adenosine deaminase 2 (dada2): approaches, obstacles and special considerations. Front Immunol. 2022;13:932385. https:\/\/doi.org\/10.3389\/fimmu.2022.932385.","journal-title":"Front Immunol"},{"key":"2906_CR30","doi-asserted-by":"publisher","unstructured":"Arnold DE, Kaviany S, Aluri J, Calvo KR, Mehta SS, Tobin JM, et al. Clinical characteristics, management, and hematopoietic cell transplantation of patients with TLR8 gain-of-function. Blood Adv. 2025. https:\/\/doi.org\/10.1182\/bloodadvances.2025016338.","DOI":"10.1182\/bloodadvances.2025016338"},{"key":"2906_CR31","doi-asserted-by":"publisher","unstructured":"Altmann T, Rao K, Hanasoge-Nataraj R, Patrick K, Carpenter B, Hough R, et al. Low rates of endothelial cell dysfunction and transplant-related mortality in 537 children receiving fludarabine-treosulfan conditioning for all transplant indications: a retrospective multicentre study on behalf of the UK Paediatric BMT group. Br J Haematol. 2025. https:\/\/doi.org\/10.1111\/bjh.20184.","DOI":"10.1111\/bjh.20184"},{"key":"2906_CR32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s10875-024-01854-y","volume":"45","author":"TA Fox","year":"2025","unstructured":"Fox TA, Massey V, Lever C, Pearce R, Laurence A, Grace S, et al. Pre-transplant immune dysregulation predicts poor outcome following allogeneic haematopoietic stem cell transplantation in adolescents and adults with inborn errors of immunity (IEI). J Clin Immunol. 2025;45:64 https:\/\/doi.org\/10.1007\/s10875-024-01854-y.","journal-title":"J Clin Immunol"},{"key":"2906_CR33","doi-asserted-by":"publisher","unstructured":"Seidel, Markus G et al. The Immune Deficiency and Dysregulation Activity (IDDA2.1 'Kaleidoscope') Score and Other Clinical Measures in Inborn Errors of Immunity. J Clin Immunol. 2022;42:484\u201398 https:\/\/doi.org\/10.1007\/s10875-021-01177-2.","DOI":"10.1007\/s10875-021-01177-2"},{"key":"2906_CR34","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1542\/peds.2005-1789","volume":"117","author":"M Ouach\u00e9e-Chardin","year":"2006","unstructured":"Ouach\u00e9e-Chardin M, Elie C, de Saint-Basile G, Le Deist F, Mahlaoui N, Picard C, et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics. 2006;117:e743\u2013750. https:\/\/doi.org\/10.1542\/peds.2005-1789.","journal-title":"Pediatrics"},{"key":"2906_CR35","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.3324\/haematol.2019.216101","volume":"104","author":"P Merli","year":"2019","unstructured":"Merli P, Caruana I, De Vito R, Strocchio L, Weber G, Del Bufalo F, et al. Role of interferon-\u03b3 in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation. Haematologica. 2019;104:2314\u201323. https:\/\/doi.org\/10.3324\/haematol.2019.216101.","journal-title":"Haematologica"},{"key":"2906_CR36","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood.2024025977","volume":"144","author":"B Verkamp","year":"2024","unstructured":"Verkamp B, Jodele S, Sabulski A, Marsh R, Kieser P, Jordan MB. Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism. Blood. 2024;144:2625\u201336. https:\/\/doi.org\/10.1182\/blood.2024025977.","journal-title":"Blood"},{"key":"2906_CR37","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaci.2021.04.039","volume":"149","author":"D Egg","year":"2022","unstructured":"Egg D, Rump IC, Mitsuiki N, Rojas-Restrepo J, Maccari ME, Schwab C, et al. Therapeutic options for CTLA-4 insufficiency. J Allergy Clin Immunol. 2022;149:736\u201346. https:\/\/doi.org\/10.1016\/j.jaci.2021.04.039.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR38","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.jaci.2023.08.004","volume":"152","author":"N Taghizade","year":"2023","unstructured":"Taghizade N, Babayeva R, Kara A, Karakus IS, Catak MC, Bulutoglu A, et al. Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency. J Allergy Clin Immunol. 2023;152:1634\u201345. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.004.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR39","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.jaci.2019.12.896","volume":"145","author":"VK Tesch","year":"2020","unstructured":"Tesch VK, Abolhassani H, Shadur B, Zobel J, Mareika Y, Sharapova S, et al. Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score. J Allergy Clin Immunol. 2020;145:1452\u201363. https:\/\/doi.org\/10.1016\/j.jaci.2019.12.896.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR40","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2022018546","volume":"141","author":"VK Rao","year":"2023","unstructured":"Rao VK, Webster S, \u0160ediv\u00e1 A, Plebani A, Schuetz C, Shcherbina A, et al. A randomized, placebo-controlled phase 3 trial of the PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome. Blood. 2023;141:971\u201383. https:\/\/doi.org\/10.1182\/blood.2022018546.","journal-title":"Blood"},{"key":"2906_CR41","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s10875-022-01236-2","volume":"42","author":"AV Geerlinks","year":"2022","unstructured":"Geerlinks AV, Dvorak AM. A case of XIAP deficiency successfully managed with tadekinig Alfa (rhIL-18BP). J Clin Immunol. 2022;42:901\u20133. https:\/\/doi.org\/10.1007\/s10875-022-01236-2.","journal-title":"J Clin Immunol"},{"key":"2906_CR42","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","volume":"25","author":"M Taylor","year":"2019","unstructured":"Taylor M, Khan S, Stapleton M, Wang J, Chen J, Wynn R, et al. Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future. Biol Blood Marrow Transplant. 2019;25:e226\u2013e246. https:\/\/doi.org\/10.1016\/j.bbmt.2019.02.012.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2906_CR43","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jaci.2017.04.035","volume":"141","author":"BE Marciano","year":"2018","unstructured":"Marciano BE, Zerbe CS, Falcone EL, Ding L, DeRavin SS, Daub J, et al. X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stability. J Allergy Clin Immunol. 2018;141:365\u201371. https:\/\/doi.org\/10.1016\/j.jaci.2017.04.035.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR44","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jaci.2013.10.021","volume":"133","author":"C Schuetz","year":"2014","unstructured":"Schuetz C, Pannicke U, Jacobsen EM, Burggraf S, Albert MH, H\u00f6nig M, et al. Lesson from hypomorphic recombination-activating gene (RAG) mutations: why asymptomatic siblings should also be tested. J Allergy Clin Immunol. 2014;133:1211\u20135. https:\/\/doi.org\/10.1016\/j.jaci.2013.10.021.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR45","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1182\/bloodadvances.2020004072","volume":"6","author":"SH Lum","year":"2022","unstructured":"Lum SH, Greener S, Perez-Heras I, Drozdov D, Payne RP, Watson H, et al. T-replete HLA-matched grafts vs T-depleted HLA-mismatched grafts in inborn errors of immunity. Blood Adv. 2022;6:1319\u201328. https:\/\/doi.org\/10.1182\/bloodadvances.2020004072.","journal-title":"Blood Adv"},{"key":"2906_CR46","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s10875-020-00898-0","volume":"41","author":"OR Klein","year":"2021","unstructured":"Klein OR, Bapty S, Lederman HM, Younger MEM, Zambidis ET, Jones RJ, et al. Reduced intensity bone marrow transplantation with post-transplant cyclophosphamide for pediatric inherited immune deficiencies and bone marrow failure syndromes. J Clin Immunol. 2021;41:414\u201326. https:\/\/doi.org\/10.1007\/s10875-020-00898-0.","journal-title":"J Clin Immunol"},{"key":"2906_CR47","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.bbmt.2019.03.009","volume":"25","author":"B Neven","year":"2019","unstructured":"Neven B, Diana JS, Castelle M, Magnani A, Rosain J, Touzot F, et al. Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children. Biol Blood Marrow Transplant. 2019;25:1363\u201373. https:\/\/doi.org\/10.1016\/j.bbmt.2019.03.009.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2906_CR48","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.3324\/haematol.2018.215285","volume":"104","author":"M Kurzay","year":"2019","unstructured":"Kurzay M, Hauck F, Schmid I, Wiebking V, Eichinger A, Jung E, et al. T-cell replete haploidentical bone marrow transplantation and post-transplant cyclophosphamide for patients with inborn errors. Haematologica. 2019;104:e478\u2013e482. https:\/\/doi.org\/10.3324\/haematol.2018.215285.","journal-title":"Haematologica"},{"key":"2906_CR49","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.jaci.2017.07.008","volume":"141","author":"RM Shah","year":"2018","unstructured":"Shah RM, Elfeky R, Nademi Z, Qasim W, Amrolia P, Chiesa R, et al. T-cell receptor \u03b1\u03b2(+) and CD19(+) cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. J Allergy Clin Immunol. 2018;141:1417\u20131426.e1411. https:\/\/doi.org\/10.1016\/j.jaci.2017.07.008.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR50","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/j.bbmt.2020.07.003","volume":"26","author":"JF Fernandes","year":"2020","unstructured":"Fernandes JF, Nichele S, Arcuri LJ, Ribeiro L, Zamperlini-Netto G, Loth G, et al. Outcomes after haploidentical stem cell transplantation with post-transplantation cyclophosphamide in patients with primary immunodeficiency diseases. Biol Blood Marrow Transplant. 2020;26:1923\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.003.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2906_CR51","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jaci.2016.01.053","volume":"138","author":"K Rao","year":"2016","unstructured":"Rao K, Adams S, Qasim W, Allwood Z, Worth A, Silva J, et al. Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen. J Allergy Clin Immunol. 2016;138:1152\u201360. https:\/\/doi.org\/10.1016\/j.jaci.2016.01.053.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR52","doi-asserted-by":"publisher","first-page":"314.e311","DOI":"10.1016\/j.jtct.2023.12.005","volume":"30","author":"SH Lum","year":"2024","unstructured":"Lum SH, James B, Ottaviano G, Ewins AM, Patrick K, Ali S, et al. Alemtuzumab, dual graft-versus-host disease prophylaxis, and lower CD3(+) T Cell doses equalize rates of acute and chronic graft-versus-host disease in pediatric patients receiving allogeneic hematopoietic stem cell transplantation with matched unrelated donor peripheral blood stem cells or bone marrow grafts. Transplant Cell Ther. 2024;30:314.e311\u2013314.e312. https:\/\/doi.org\/10.1016\/j.jtct.2023.12.005.","journal-title":"Transplant Cell Ther"},{"key":"2906_CR53","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/bjh.13802","volume":"172","author":"R Hough","year":"2016","unstructured":"Hough R, Danby R, Russell N, Marks D, Veys P, Shaw B, et al. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. Br J Haematol. 2016;172:360\u201370. https:\/\/doi.org\/10.1111\/bjh.13802.","journal-title":"Br J Haematol"},{"key":"2906_CR54","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jtct.2023.09.006","volume":"29","author":"I Politikos","year":"2023","unstructured":"Politikos I. Role of CD34+ Cell dose and allele-level HLA matching in single-unit cord blood transplantation. Transplant Cell Ther. 2023;29:589\u201391. https:\/\/doi.org\/10.1016\/j.jtct.2023.09.006.","journal-title":"Transplant Cell Ther"},{"key":"2906_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.826004","volume":"13","author":"M van der Stoep","year":"2022","unstructured":"van der Stoep M, Oostenbrink LVE, Bredius RGM, Moes D, Guchelaar HJ, Zwaveling J, et al. Therapeutic drug monitoring of conditioning agents in pediatric allogeneic stem cell transplantation: where do we stand? Front Pharmacol. 2022;13:826004. https:\/\/doi.org\/10.3389\/fphar.2022.826004.","journal-title":"Front Pharmacol"},{"key":"2906_CR56","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/s41409-024-02413-0","volume":"59","author":"V Domingos","year":"2024","unstructured":"Domingos V, Nezvalova-Henriksen K, Dadkhah A, Moreno-Martinez ME, Ben Hassine K, Pires V, et al. A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2024;59:1641\u201353. https:\/\/doi.org\/10.1038\/s41409-024-02413-0.","journal-title":"Bone Marrow Transplant"},{"key":"2906_CR57","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.bbmt.2017.06.021","volume":"23","author":"V Ivaturi","year":"2017","unstructured":"Ivaturi V, Dvorak CC, Chan D, Liu T, Cowan MJ, Wahlstrom J, et al. Pharmacokinetics and model-based dosing to optimize fludarabine therapy in pediatric hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2017;23:1701\u201313. https:\/\/doi.org\/10.1016\/j.bbmt.2017.06.021.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2906_CR58","doi-asserted-by":"publisher","unstructured":"Brooks JT, Solans BP, Lu Y, Kharbanda S, Dvorak CC, Lalefar N, et al. Prospective validation and refinement of a population pharmacokinetic model of fludarabine in children and young adults undergoing hematopoietic cell transplantation. Pharmaceutics 2022; 14. https:\/\/doi.org\/10.3390\/pharmaceutics14112462.","DOI":"10.3390\/pharmaceutics14112462"},{"key":"2906_CR59","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s40262-018-0715-9","volume":"58","author":"JB Langenhorst","year":"2019","unstructured":"Langenhorst JB, Dorlo TPC, van Maarseveen EM, Nierkens S, Kuball J, Boelens JJ, et al. Population pharmacokinetics of fludarabine in children and adults during conditioning prior to allogeneic hematopoietic cell transplantation. Clin Pharmacokinet. 2019;58:627\u201337. https:\/\/doi.org\/10.1007\/s40262-018-0715-9.","journal-title":"Clin Pharmacokinet"},{"key":"2906_CR60","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/cpt.1715","volume":"108","author":"R Chiesa","year":"2020","unstructured":"Chiesa R, Standing JF, Winter R, Nademi Z, Chu J, Pinner D, et al. Proposed therapeutic range of treosulfan in reduced toxicity pediatric allogeneic hematopoietic stem cell transplant conditioning: results from a prospective trial. Clin Pharmacol Ther. 2020;108:264\u201373. https:\/\/doi.org\/10.1002\/cpt.1715.","journal-title":"Clin Pharmacol Ther"},{"key":"2906_CR61","doi-asserted-by":"publisher","first-page":"99.e91","DOI":"10.1016\/j.jtct.2021.09.018","volume":"28","author":"M van der Stoep","year":"2022","unstructured":"van der Stoep M, Bertaina A, Moes D, Algeri M, Bredius RGM, Smiers FJW, et al. Impact of treosulfan exposure on early and long-term clinical outcomes in pediatric allogeneic hematopoietic stem cell transplantation recipients: a prospective multicenter study. Transplant Cell Ther. 2022;28:99.e91\u201399.e97. https:\/\/doi.org\/10.1016\/j.jtct.2021.09.018.","journal-title":"Transplant Cell Ther"},{"key":"2906_CR62","doi-asserted-by":"publisher","first-page":"259.e251","DOI":"10.1016\/j.jtct.2025.02.002","volume":"31","author":"CC Dvorak","year":"2025","unstructured":"Dvorak CC, Temple WC, Cisneros GS, Chu J, Winestone LE, Higham CS, et al. Younger children with nonmalignant disease have an increased incidence of mixed myeloid chimerism after allogeneic hematopoietic cell transplantation with busulfan-based conditioning. Transplant Cell Ther. 2025;31:259.e251\u2013259.e215. https:\/\/doi.org\/10.1016\/j.jtct.2025.02.002.","journal-title":"Transplant Cell Ther"},{"key":"2906_CR63","doi-asserted-by":"publisher","first-page":"101.e101","DOI":"10.1016\/j.jtct.2023.09.024","volume":"30","author":"T Fitch","year":"2024","unstructured":"Fitch T, Lane A, McDonnell J, Bleesing J, Jordan M, Kumar A, et al. Age impacts the risk of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for non-severe combined immune deficiency inborn errors of immunity. Transplant Cell Ther. 2024;30:101.e101\u2013101.e112. https:\/\/doi.org\/10.1016\/j.jtct.2023.09.024.","journal-title":"Transplant Cell Ther"},{"key":"2906_CR64","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s40262-019-00782-0","volume":"58","author":"R Admiraal","year":"2019","unstructured":"Admiraal R, Jol-van der Zijde CM, Furtado Silva JM, Knibbe CAJ, Lankester AC, Boelens JJ, et al. Population pharmacokinetics of alemtuzumab (Campath) in pediatric hematopoietic cell transplantation: towards individualized dosing to improve outcome. Clin Pharmacokinet. 2019;58:1609\u201320. https:\/\/doi.org\/10.1007\/s40262-019-00782-0.","journal-title":"Clin Pharmacokinet"},{"key":"2906_CR65","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fimmu.2019.00315","volume":"10","author":"LVE Oostenbrink","year":"2019","unstructured":"Oostenbrink LVE, Jol-van der Zijde CM, Kielsen K, Jansen-Hoogendijk AM, Ifversen M, M\u00fcller KG, et al. Differential elimination of anti-thymocyte globulin of Fresenius and Genzyme impacts T-cell reconstitution after hematopoietic stem cell transplantation. Front Immunol. 2019;10:315 https:\/\/doi.org\/10.3389\/fimmu.2019.00315.","journal-title":"Front Immunol"},{"key":"2906_CR66","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1182\/bloodadvances.2022009051","volume":"7","author":"FR Achini-Gutzwiller","year":"2023","unstructured":"Achini-Gutzwiller FR, Schilham MW, von Asmuth EGJ, Jansen-Hoogendijk AM, Jol-van der Zijde CM, van Tol MJD, et al. Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study. Blood Adv. 2023;7:4462\u201374. https:\/\/doi.org\/10.1182\/bloodadvances.2022009051.","journal-title":"Blood Adv"},{"key":"2906_CR67","doi-asserted-by":"publisher","unstructured":"Pfeiffer T, Murray L, Gao F, Shenoy S, Mavers M, Hayashi RJ et al. Alemtuzumab, fludarabine, melphalan, and thiotepa conditioning for transplantation in inborn errors of immunity. Transplant Cell Ther 2025. https:\/\/doi.org\/10.1016\/j.jtct.2025.11.028.","DOI":"10.1016\/j.jtct.2025.11.028"},{"key":"2906_CR68","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaci.2021.07.031","volume":"149","author":"RA Marsh","year":"2022","unstructured":"Marsh RA, Hebert K, Kim S, Dvorak CC, Aquino VM, Baker KS, et al. Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders. J Allergy Clin Immunol. 2022;149:1097\u20131104.e1092. https:\/\/doi.org\/10.1016\/j.jaci.2021.07.031.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR69","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2165\/11598180-000000000-00000","volume":"51","author":"IH Bartelink","year":"2012","unstructured":"Bartelink IH, Boelens JJ, Bredius RG, Egberts AC, Wang C, Bierings MB, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet. 2012;51:331\u201345. https:\/\/doi.org\/10.2165\/11598180-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"2906_CR70","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1016\/s2352-3026(16)30114-4","volume":"3","author":"IH Bartelink","year":"2016","unstructured":"Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016;3:e526\u2013e536. https:\/\/doi.org\/10.1016\/s2352-3026(16)30114-4.","journal-title":"Lancet Haematol"},{"key":"2906_CR71","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1182\/bloodadvances.2024013275","volume":"8","author":"T Bogn\u00e0r","year":"2024","unstructured":"Bogn\u00e0r T, Garcia-Rosa M, Lalmohamed A, G\u00fcng\u00f6r T, Hauri-Hohl M, Prockop S, et al. Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity. Blood Adv. 2024;8:5137\u201345. https:\/\/doi.org\/10.1182\/bloodadvances.2024013275.","journal-title":"Blood Adv"},{"key":"2906_CR72","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41409-023-01971-z","volume":"58","author":"TT Bogn\u00e0r","year":"2023","unstructured":"Bogn\u00e0r TT, Kingma JSJ, Smeijsters EHE, van der Elst K, de Kanter C, Lindemans CAC, et al. Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen. Bone Marrow Transplant. 2023;58:762\u20138. https:\/\/doi.org\/10.1038\/s41409-023-01971-z.","journal-title":"Bone Marrow Transplant"},{"key":"2906_CR73","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.bbmt.2013.08.014","volume":"19","author":"RM Savic","year":"2013","unstructured":"Savic RM, Cowan MJ, Dvorak CC, Pai SY, Pereira L, Bartelink IH, et al. Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1608\u201314. https:\/\/doi.org\/10.1016\/j.bbmt.2013.08.014.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2906_CR74","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/bmt.2015.171","volume":"50","author":"MA Slatter","year":"2015","unstructured":"Slatter MA, Boztug H, P\u00f6tschger U, Sykora KW, Lankester A, Yaniv I, et al. Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases. Bone Marrow Transplant. 2015;50:1536\u201341. https:\/\/doi.org\/10.1038\/bmt.2015.171.","journal-title":"Bone Marrow Transplant"},{"key":"2906_CR75","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2016-03-704015","volume":"128","author":"B Morillo-Gutierrez","year":"2016","unstructured":"Morillo-Gutierrez B, Beier R, Rao K, Burroughs L, Schulz A, Ewins AM, et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood. 2016;128:440\u20138. https:\/\/doi.org\/10.1182\/blood-2016-03-704015.","journal-title":"Blood"},{"key":"2906_CR76","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/s41409-022-01755-x","volume":"57","author":"LC de Kloet","year":"2022","unstructured":"de Kloet LC, Bense JE, van der Stoep M, Louwerens M, von Asmuth EGJ, Lankester AC, et al. Late endocrine effects after hematopoietic stem cell transplantation in children with nonmalignant diseases. Bone Marrow Transplant. 2022;57:1564\u201372. https:\/\/doi.org\/10.1038\/s41409-022-01755-x.","journal-title":"Bone Marrow Transplant"},{"key":"2906_CR77","doi-asserted-by":"publisher","first-page":"529.e521","DOI":"10.1016\/j.jtct.2023.05.003","volume":"29","author":"M van der Stoep","year":"2023","unstructured":"van der Stoep M, Bense JE, de Kloet LC, von Asmuth EGJ, de Pagter APJ, Hannema SE, et al. Effect of busulfan and treosulfan on gonadal function after allogeneic stem cell transplantation in children and adolescents with nonmalignant diseases is not exposure-dependent. Transplant Cell Ther. 2023;29:529.e521\u2013529.e525. https:\/\/doi.org\/10.1016\/j.jtct.2023.05.003.","journal-title":"Transplant Cell Ther"},{"key":"2906_CR78","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41409-023-02135-9","volume":"59","author":"KW Sykora","year":"2024","unstructured":"Sykora KW, Beier R, Schulz A, Cesaro S, Greil J, Gozdzik J, et al. Treosulfan vs busulfan conditioning for allogeneic BMT in children with nonmalignant disease: a randomized phase 2 trial. Bone Marrow Transplant. 2024;59:107\u201316. https:\/\/doi.org\/10.1038\/s41409-023-02135-9.","journal-title":"Bone Marrow Transplant"},{"key":"2906_CR79","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/bjh.14960","volume":"179","author":"M van der Stoep","year":"2017","unstructured":"van der Stoep M, Bertaina A, Ten Brink MH, Bredius RG, Smiers FJ, Wanders DCM, et al. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study. Br J Haematol. 2017;179:772\u201380. https:\/\/doi.org\/10.1111\/bjh.14960.","journal-title":"Br J Haematol"},{"key":"2906_CR80","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/bcp.16339","volume":"91","author":"K Kalwak","year":"2025","unstructured":"Kalwak K, Vora A, Bader P, Burkhardt B, Corbacioglu S, Drabko K, et al. Impact of treosulfan exposure on clinical outcome after allogeneic stem cell transplantation in children: a substudy of 2 phase 2 trials. Br J Clin Pharmacol. 2025;91:882\u201393. https:\/\/doi.org\/10.1111\/bcp.16339.","journal-title":"Br J Clin Pharmacol"},{"key":"2906_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2023.100515","volume":"52","author":"X Li","year":"2023","unstructured":"Li X, Kalwak K, Beier R, Kehne J, M\u00f6ller AK, Baumgart J, et al. Population pharmacokinetic modeling of treosulfan and rationale for dose recommendation in children treated for conditioning prior to allogeneic hematopoietic stem cell transplantation. Drug Metab Pharmacokinet. 2023;52:100515. https:\/\/doi.org\/10.1016\/j.dmpk.2023.100515.","journal-title":"Drug Metab Pharmacokinet"},{"key":"2906_CR82","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1111\/bcp.13995","volume":"85","author":"M van der Stoep","year":"2019","unstructured":"van der Stoep M, Zwaveling J, Bertaina A, Locatelli F, Guchelaar HJ, Lankester AC, et al. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation. Br J Clin Pharmacol. 2019;85:2033\u201344. https:\/\/doi.org\/10.1111\/bcp.13995.","journal-title":"Br J Clin Pharmacol"},{"key":"2906_CR83","doi-asserted-by":"publisher","unstructured":"Balis FM, Womer RB, Berg S, Winick N, Adamson PC, Fox E. Dosing anticancer drugs in infants: Current approach and recommendations from the Children\u2019s Oncology Group\u2019s Chemotherapy Standardization Task Force. Pediatr Blood Cancer 2017; 64. https:\/\/doi.org\/10.1002\/pbc.26636.","DOI":"10.1002\/pbc.26636"},{"key":"2906_CR84","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41409-018-0260-z","volume":"54","author":"H Chung","year":"2019","unstructured":"Chung H, Hong KT, Lee JW, Rhee SJ, Kim S, Yoon SH, et al. Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients. Bone Marrow Transplant. 2019;54:284\u201392. https:\/\/doi.org\/10.1038\/s41409-018-0260-z.","journal-title":"Bone Marrow Transplant"},{"key":"2906_CR85","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jaci.2017.02.036","volume":"141","author":"J Slack","year":"2018","unstructured":"Slack J, Albert MH, Balashov D, Belohradsky BH, Bertaina A, Bleesing J, et al. Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. J Allergy Clin Immunol. 2018;141:322\u2013328.e310. https:\/\/doi.org\/10.1016\/j.jaci.2017.02.036.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR86","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00228-013-1507-7","volume":"69","author":"IW Kim","year":"2013","unstructured":"Kim IW, Yun HY, Choi B, Han N, Kim MG, Park S, et al. Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation. Eur J Clin Pharmacol. 2013;69:1543\u201351. https:\/\/doi.org\/10.1007\/s00228-013-1507-7.","journal-title":"Eur J Clin Pharmacol"},{"key":"2906_CR87","doi-asserted-by":"publisher","first-page":"931.e931","DOI":"10.1016\/j.jtct.2024.06.020","volume":"30","author":"CS Higham","year":"2024","unstructured":"Higham CS, Shimano KA, Kharbanda S, Chu J, Cisneros GS, Winestone LE, et al. Cyclophosphamide and thiotepa increase the risk of transplant-associated thrombotic microangiopathy. Transplant Cell Ther. 2024;30:931.e931\u2013931.e910. https:\/\/doi.org\/10.1016\/j.jtct.2024.06.020.","journal-title":"Transplant Cell Ther"},{"key":"2906_CR88","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1182\/blood.V96.4.1239","volume":"96","author":"P Amrolia","year":"2000","unstructured":"Amrolia P, Gaspar HB, Hassan A, Webb D, Jones A, Sturt N, et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood. 2000;96:1239\u201346.","journal-title":"Blood"},{"key":"2906_CR89","doi-asserted-by":"publisher","first-page":"384.e381","DOI":"10.1016\/j.jtct.2025.03.020","volume":"31","author":"CC Dvorak","year":"2025","unstructured":"Dvorak CC, Cho S, Salinas Cisneros G, Higham CS, Chu J, Winestone LE, et al. High melphalan exposure increases the risk of graft-versus-host disease in pediatric patients undergoing alpha-beta T-cell-depleted haploidentical transplantation. Transplant Cell Ther. 2025;31:384.e381\u2013384.e315. https:\/\/doi.org\/10.1016\/j.jtct.2025.03.020.","journal-title":"Transplant Cell Ther"},{"key":"2906_CR90","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40262-021-01093-z","volume":"61","author":"GL Shah","year":"2022","unstructured":"Shah GL, Boelens JJ, Carlow D, Lin A, Schofield R, Cruz Sitner N, et al. Population pharmacokinetics of melphalan in a large cohort of autologous and allogeneic hematopoietic cell transplantation recipients: towards individualized dosing regimens. Clin Pharmacokinet. 2022;61:553\u201363. https:\/\/doi.org\/10.1007\/s40262-021-01093-z.","journal-title":"Clin Pharmacokinet"},{"key":"2906_CR91","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/s0140-6736(13)62069-3","volume":"383","author":"T G\u00fcng\u00f6r","year":"2014","unstructured":"G\u00fcng\u00f6r T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383:436\u201348. https:\/\/doi.org\/10.1016\/s0140-6736(13)62069-3.","journal-title":"Lancet"},{"key":"2906_CR92","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/s2352-3026(15)00045-9","volume":"2","author":"R Admiraal","year":"2015","unstructured":"Admiraal R, van Kesteren C, Jol-van der Zijde CM, Lankester AC, Bierings MB, Egberts TC, et al. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol. 2015;2:e194\u2013203. https:\/\/doi.org\/10.1016\/s2352-3026(15)00045-9.","journal-title":"Lancet Haematol"},{"key":"2906_CR93","doi-asserted-by":"publisher","first-page":"263.e261","DOI":"10.1016\/j.jtct.2025.01.893","volume":"31","author":"D Drozdov","year":"2025","unstructured":"Drozdov D, Kandil J, Long SE, Demorest CV, Cao Q, Lund TC, et al. Bodyweight and absolute lymphocyte count-based dosing of rabbit anti-thymocyte globulin results in early CD4(+) immune reconstitution in patients with inborn errors of metabolism undergoing umbilical cord blood transplantation. Transplant Cell Ther. 2025;31:263.e261\u2013263.e267. https:\/\/doi.org\/10.1016\/j.jtct.2025.01.893.","journal-title":"Transplant Cell Ther"},{"key":"2906_CR94","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41409-020-0792-x","volume":"55","author":"F Bonifazi","year":"2020","unstructured":"Bonifazi F, Rubio MT, Bacigalupo A, Boelens JJ, Finke J, Greinix H, et al. Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. Bone Marrow Transplant. 2020;55:1093\u2013102. https:\/\/doi.org\/10.1038\/s41409-020-0792-x.","journal-title":"Bone Marrow Transplant"},{"key":"2906_CR95","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1182\/blood-2016-06-721936","volume":"128","author":"R Admiraal","year":"2016","unstructured":"Admiraal R, Lindemans CA, van Kesteren C, Bierings MB, Versluijs AB, Nierkens S, et al. Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. Blood. 2016;128:2734\u201341. https:\/\/doi.org\/10.1182\/blood-2016-06-721936.","journal-title":"Blood"},{"key":"2906_CR96","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaci.2022.10.022","volume":"151","author":"CC Dvorak","year":"2023","unstructured":"Dvorak CC, Haddad E, Heimall J, Dunn E, Buckley RH, Kohn DB, et al. The diagnosis of severe combined immunodeficiency (SCID): the primary immune deficiency treatment consortium (PIDTC) 2022 definitions. J Allergy Clin Immunol. 2023;151:539\u201346. https:\/\/doi.org\/10.1016\/j.jaci.2022.10.022.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR97","doi-asserted-by":"publisher","unstructured":"Lee YN, Frugoni F, Dobbs K, Tirosh I, Du L, Ververs FA et al. Characterization of T and B cell repertoire diversity in patients with RAG deficiency. Sci Immunol 2016; 1. https:\/\/doi.org\/10.1126\/sciimmunol.aah6109.","DOI":"10.1126\/sciimmunol.aah6109"},{"key":"2906_CR98","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.jaci.2024.07.031","volume":"154","author":"AY Kreins","year":"2024","unstructured":"Kreins AY, Dhalla F, Flinn AM, Howley E, Ekwall O, Villa A, et al. European Society for Immunodeficiencies guidelines for the management of patients with congenital athymia. J Allergy Clin Immunol. 2024;154:1391\u2013408. https:\/\/doi.org\/10.1016\/j.jaci.2024.07.031.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR99","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.jaip.2023.01.032","volume":"11","author":"E Grunebaum","year":"2023","unstructured":"Grunebaum E, Booth C, Cuvelier GDE, Loves R, Aiuti A, Kohn DB. Updated management guidelines for adenosine deaminase deficiency. J Allergy Clin Immunol Pr. 2023;11:1665\u201375. https:\/\/doi.org\/10.1016\/j.jaip.2023.01.032.","journal-title":"J Allergy Clin Immunol Pr"},{"key":"2906_CR100","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1182\/blood-2018-03-840702","volume":"132","author":"E Haddad","year":"2018","unstructured":"Haddad E, Logan BR, Griffith LM, Buckley RH, Parrott RE, Prockop SE, et al. SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood. 2018;132:1737\u201349. https:\/\/doi.org\/10.1182\/blood-2018-03-840702.","journal-title":"Blood"},{"key":"2906_CR101","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fped.2019.00481","volume":"7","author":"E Haddad","year":"2019","unstructured":"Haddad E, Hoenig M. Hematopoietic stem cell transplantation for severe combined immunodeficiency (SCID). Front Pediatr. 2019;7:481 https:\/\/doi.org\/10.3389\/fped.2019.00481.","journal-title":"Front Pediatr"},{"key":"2906_CR102","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jaci.2014.06.021","volume":"134","author":"CC Dvorak","year":"2014","unstructured":"Dvorak CC, Hassan A, Slatter MA, H\u00f6nig M, Lankester AC, Buckley RH, et al. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. J Allergy Clin Immunol. 2014;134:935\u2013943.e915. https:\/\/doi.org\/10.1016\/j.jaci.2014.06.021.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR103","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3389\/fped.2019.00557","volume":"7","author":"B Wolska-Ku\u015bnierz","year":"2019","unstructured":"Wolska-Ku\u015bnierz B, Gennery AR. Hematopoietic stem cell transplantation for DNA double-strand breakage repair disorders. Front Pediatr. 2019;7:557 https:\/\/doi.org\/10.3389\/fped.2019.00557.","journal-title":"Front Pediatr"},{"key":"2906_CR104","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/s0960-9822(99)80311-x","volume":"9","author":"E Riballo","year":"1999","unstructured":"Riballo E, Critchlow SE, Teo SH, Doherty AJ, Priestley A, Broughton B, et al. Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curr Biol. 1999;9:699\u2013702. https:\/\/doi.org\/10.1016\/s0960-9822(99)80311-x.","journal-title":"Curr Biol"},{"key":"2906_CR105","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/j.1365-2141.2011.08863.x","volume":"155","author":"K Bienemann","year":"2011","unstructured":"Bienemann K, Burkhardt B, Modlich S, Meyer U, M\u00f6ricke A, Bienemann K, et al. Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey. Br J Haematol. 2011;155:468\u201376. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08863.x.","journal-title":"Br J Haematol"},{"key":"2906_CR106","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood.2022015482","volume":"141","author":"M Cheminant","year":"2023","unstructured":"Cheminant M, Fox TA, Alligon M, Bouaziz O, Neven B, Moshous D, et al. Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity. Blood. 2023;141:60\u201371. https:\/\/doi.org\/10.1182\/blood.2022015482.","journal-title":"Blood"},{"key":"2906_CR107","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1182\/blood-2017-09-807487","volume":"131","author":"TA Fox","year":"2018","unstructured":"Fox TA, Chakraverty R, Burns S, Carpenter B, Thomson K, Lowe D, et al. Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. Blood. 2018;131:917\u201331. https:\/\/doi.org\/10.1182\/blood-2017-09-807487.","journal-title":"Blood"},{"key":"2906_CR108","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jaip.2017.07.045","volume":"6","author":"MH Albert","year":"2018","unstructured":"Albert MH, Hauck F, Wiebking V, Aydin S, Notheis G, Koletzko S, et al. Allogeneic stem cell transplantation in adolescents and young adults with primary immunodeficiencies. J Allergy Clin Immunol Pr. 2018;6:298\u2013301.e292. https:\/\/doi.org\/10.1016\/j.jaip.2017.07.045.","journal-title":"J Allergy Clin Immunol Pr"},{"key":"2906_CR109","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood.2020008187","volume":"138","author":"SO Burns","year":"2021","unstructured":"Burns SO, Morris EC. How I use allogeneic HSCT for adults with inborn errors of immunity. Blood. 2021;138:1666\u201376. https:\/\/doi.org\/10.1182\/blood.2020008187.","journal-title":"Blood"},{"key":"2906_CR110","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1182\/bloodadvances.2018025890","volume":"3","author":"P Stepensky","year":"2019","unstructured":"Stepensky P, Grisariu S, Avni B, Zaidman I, Shadur B, Elpeleg O, et al. Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years. Blood Adv. 2019;3:862\u20138. https:\/\/doi.org\/10.1182\/bloodadvances.2018025890.","journal-title":"Blood Adv"},{"key":"2906_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116634","volume":"167","author":"A Schulz","year":"2023","unstructured":"Schulz A, Moshous D. Hematopoietic stem cell transplantation, a curative approach in infantile osteopetrosis. Bone. 2023;167:116634. https:\/\/doi.org\/10.1016\/j.bone.2022.116634.","journal-title":"Bone"},{"key":"2906_CR112","doi-asserted-by":"crossref","unstructured":"Chiesa R, Albert MH, Gilbert P, Knippenberg J, Zaidman I, Alsaedi H, et al. Hematopoietic stem cell transplantation in 746 children with osteopetrosis: a study of the inborn errors working party of the EBMT. Blood 2025; 146: 165\u20135.","DOI":"10.1182\/blood-2025-165"},{"key":"2906_CR113","doi-asserted-by":"publisher","unstructured":"Ezgu F. Inborn errors of metabolism. Adv Clin Chem. 2016; 73: 195\u2013250. https:\/\/doi.org\/10.1016\/bs.acc.2015.12.001.","DOI":"10.1016\/bs.acc.2015.12.001"},{"key":"2906_CR114","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3389\/fped.2019.00433","volume":"7","author":"EY Tan","year":"2019","unstructured":"Tan EY, Boelens JJ, Jones SA, Wynn RF. Hematopoietic stem cell transplantation in inborn errors of metabolism. Front Pediatr. 2019;7:433 https:\/\/doi.org\/10.3389\/fped.2019.00433.","journal-title":"Front Pediatr"},{"key":"2906_CR115","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ymgme.2016.01.011","volume":"117","author":"A Ghosh","year":"2016","unstructured":"Ghosh A, Miller W, Orchard PJ, Jones SA, Mercer J, Church HJ, et al. Enzyme replacement therapy prior to haematopoietic stem cell transplantation in Mucopolysaccharidosis Type I: 10-year combined experience of 2 centres. Mol Genet Metab. 2016;117:373\u20137. https:\/\/doi.org\/10.1016\/j.ymgme.2016.01.011.","journal-title":"Mol Genet Metab"},{"key":"2906_CR116","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01849-7","volume":"16","author":"JE Potter","year":"2021","unstructured":"Potter JE, Petts G, Ghosh A, White FJ, Kinsella JL, Hughes S, et al. Enzyme replacement therapy and hematopoietic stem cell transplant: a new paradigm of treatment in Wolman disease. Orphanet J Rare Dis. 2021;16:235. https:\/\/doi.org\/10.1186\/s13023-021-01849-7.","journal-title":"Orphanet J Rare Dis"},{"key":"2906_CR117","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10545-012-9500-3","volume":"36","author":"DH Wiseman","year":"2013","unstructured":"Wiseman DH, Mercer J, Tylee K, Malaiya N, Bonney DK, Jones SA, et al. Management of mucopolysaccharidosis type IH (Hurler\u2019s syndrome) presenting in infancy with severe dilated cardiomyopathy: a single institution\u2019s experience. J Inherit Metab Dis. 2013;36:263\u201370. https:\/\/doi.org\/10.1007\/s10545-012-9500-3.","journal-title":"J Inherit Metab Dis"},{"key":"2906_CR118","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","volume":"125","author":"M Aldenhoven","year":"2015","unstructured":"Aldenhoven M, Wynn RF, Orchard PJ, O\u2019Meara A, Veys P, Fischer A, et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125:2164\u201372. https:\/\/doi.org\/10.1182\/blood-2014-11-608075.","journal-title":"Blood"},{"key":"2906_CR119","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1182\/bloodadvances.2021006094","volume":"6","author":"KM Page","year":"2022","unstructured":"Page KM, Ream MA, Rangarajan HG, Galindo R, Mian AY, Ho ML, et al. Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease. Blood Adv. 2022;6:2947\u201356. https:\/\/doi.org\/10.1182\/bloodadvances.2021006094.","journal-title":"Blood Adv"},{"key":"2906_CR120","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.hoc.2022.03.012","volume":"36","author":"G Consiglieri","year":"2022","unstructured":"Consiglieri G, Bernardo ME, Brunetti-Pierri N, Aiuti A. Ex vivo and in vivo gene therapy for mucopolysaccharidoses: state of the art. Hematol Oncol Clin North Am. 2022;36:865\u201378. https:\/\/doi.org\/10.1016\/j.hoc.2022.03.012.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2906_CR121","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1073\/pnas.1205858109","volume":"109","author":"A Capotondo","year":"2012","unstructured":"Capotondo A, Milazzo R, Politi LS, Quattrini A, Palini A, Plati T, et al. Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation. Proc Natl Acad Sci USA. 2012;109:15018\u201323. https:\/\/doi.org\/10.1073\/pnas.1205858109.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2906_CR122","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41409-021-01465-w","volume":"57","author":"R Nataraj","year":"2022","unstructured":"Nataraj R, Hiwarkar P, Bonney D, Campbell H, Jones S, Deambrosis D, et al. B-cell depletion abrogates immune-mediated cytopenia and rejection of cord blood transplantation in Hurler syndrome. Bone Marrow Transplant. 2022;57:38\u201342. https:\/\/doi.org\/10.1038\/s41409-021-01465-w.","journal-title":"Bone Marrow Transplant"},{"key":"2906_CR123","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1182\/blood-2012-09-455238","volume":"121","author":"JJ Boelens","year":"2013","unstructured":"Boelens JJ, Aldenhoven M, Purtill D, Ruggeri A, Defor T, Wynn R, et al. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood. 2013;121:3981\u20137. https:\/\/doi.org\/10.1182\/blood-2012-09-455238.","journal-title":"Blood"},{"key":"2906_CR124","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/s0140-6736(21)02017-1","volume":"399","author":"F Fumagalli","year":"2022","unstructured":"Fumagalli F, Calbi V, Natali Sora MG, Sessa M, Baldoli C, Rancoita PMV, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access. Lancet. 2022;399:372\u201383. https:\/\/doi.org\/10.1016\/s0140-6736(21)02017-1.","journal-title":"Lancet"},{"key":"2906_CR125","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11940-019-0605-y","volume":"21","author":"EJ Mallack","year":"2019","unstructured":"Mallack EJ, Turk B, Yan H, Eichler FS. The landscape of hematopoietic stem cell transplant and gene therapy for X-linked adrenoleukodystrophy. Curr Treat Options Neurol. 2019;21:61 https:\/\/doi.org\/10.1007\/s11940-019-0605-y.","journal-title":"Curr Treat Options Neurol"},{"key":"2906_CR126","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1056\/NEJMoa2400442","volume":"391","author":"F Eichler","year":"2024","unstructured":"Eichler F, Duncan CN, Musolino PL, Lund TC, Gupta AO, De Oliveira S, et al. Lentiviral gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2024;391:1302\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2400442.","journal-title":"N Engl J Med"},{"key":"2906_CR127","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","volume":"391","author":"CN Duncan","year":"2024","unstructured":"Duncan CN, Bledsoe JR, Grzywacz B, Beckman A, Bonner M, Eichler FS, et al. Hematologic cancer after gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2024;391:1287\u2013301. https:\/\/doi.org\/10.1056\/NEJMoa2405541.","journal-title":"N Engl J Med"},{"key":"2906_CR128","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41409-025-02524-2","volume":"60","author":"JR Passweg","year":"2025","unstructured":"Passweg JR, Baldomero H, Atlija M, Kleovoulou I, Witaszek A, Alexander T, et al. The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT. Bone Marrow Transplant. 2025;60:519\u201328. https:\/\/doi.org\/10.1038\/s41409-025-02524-2.","journal-title":"Bone Marrow Transplant"},{"key":"2906_CR129","doi-asserted-by":"crossref","unstructured":"Srivastava A, Duarte FB, Faulkner L. Feasibility and experiences of HCT in resource-constrained settings. In: Sureda A, Corbacioglu S, Greco R, Kr\u00f6ger N, Carreras E (eds). The EBMT handbook: hematopoietic cell transplantation and cellular therapies. Springer: Cham; 2024.","DOI":"10.1007\/978-3-031-44080-9_69"},{"key":"2906_CR130","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood-2014-03-563817","volume":"124","author":"A Bertaina","year":"2014","unstructured":"Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant disorders. Blood. 2014;124:822\u20136. https:\/\/doi.org\/10.1182\/blood-2014-03-563817.","journal-title":"Blood"},{"key":"2906_CR131","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.bbmt.2015.07.008","volume":"21","author":"D Balashov","year":"2015","unstructured":"Balashov D, Shcherbina A, Maschan M, Trakhtman P, Skvortsova Y, Shelikhova L, et al. Single-center experience of unrelated and haploidentical stem cell transplantation with tcralphabeta and CD19 depletion in children with primary immunodeficiency syndromes. Biol Blood Marrow Transpl. 2015;21:1955\u201362. https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.008.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2906_CR132","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.jaci.2017.07.008","volume":"141","author":"RM Shah","year":"2018","unstructured":"Shah RM, Elfeky R, Nademi Z, Qasim W, Amrolia P, Chiesa R, et al. T-cell receptor alphabeta(+) and CD19(+) cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. J Allergy Clin Immunol. 2018;141:1417\u201326. https:\/\/doi.org\/10.1016\/j.jaci.2017.07.008.","journal-title":"J Allergy Clin Immunol"},{"key":"2906_CR133","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.bbmt.2020.05.001","volume":"26","author":"A Im","year":"2020","unstructured":"Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, et al. Risk factors for graft-versus-host disease in haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide. Biol Blood Marrow Transpl. 2020;26:1459\u201368. https:\/\/doi.org\/10.1016\/j.bbmt.2020.05.001.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2906_CR134","doi-asserted-by":"publisher","first-page":"6003","DOI":"10.1182\/bloodadvances.2024012670","volume":"8","author":"CC Dvorak","year":"2024","unstructured":"Dvorak CC, Long-Boyle JR, Holbrook-Brown L, Abdel-Azim H, Bertaina A, Vatsayan A, et al. Effect of rabbit ATG PK on outcomes after TCR-\u03b1\u03b2\/CD19-depleted pediatric haploidentical HCT for hematologic malignancy. Blood Adv. 2024;8:6003\u201314. https:\/\/doi.org\/10.1182\/bloodadvances.2024012670.","journal-title":"Blood Adv"},{"key":"2906_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2025.110453","volume":"274","author":"ZM Golwala","year":"2025","unstructured":"Golwala ZM, Spiridou Goncalves H, Moirangthem RD, Evans G, Lizot S, de Koning C, et al. Ex vivo T-lymphopoiesis assays assisting corrective treatment choice for genetically undefined T-lymphocytopenia. Clin Immunol. 2025;274:110453. https:\/\/doi.org\/10.1016\/j.clim.2025.110453.","journal-title":"Clin Immunol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02906-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02906-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02906-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:59:14Z","timestamp":1783601954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02906-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":135,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2906"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02906-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}